Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status.

In conclusion, KRAS (G→A) mutation does not affect in vivo anti-cancer efficacy of Cetuximab.
PMID: 24467518 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - January 27, 2014 Category: Cancer & Oncology Authors: Shi M, Shi H, Ji J, Cai Q, Chen X, Yu Y, Liu B, Zhu Z, Zhang J Tags: Curr Cancer Drug Targets Source Type: research